PURPOSE: We evaluated the population pharmacokinetics (PK) and exposure-response relationship of nilotinib in patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML). METHODS: Concentration data from 493 patients with CML in chronic phase (CML-CP), accelerated phase, or blast crisis were used to perform a population pharmacokinetic analysis using nonlinear mixed-effect modeling. Steady-state nilotinib trough concentrations (Cmin) in individual patients were estimated from the population PK model for correlation with the efficacy and safety variables. Exposure-efficacy analysis was performed in patients with CML-CP, whereas exposure-safety analysis was performed in all patients who had both nilotinib PK data and efficacy/safety measures available. RESULTS: Baseline demographics and CML disease phase did not significantly affect nilotinib PK. Patients with a lower Cmin had significantly longer time to complete cytogenetic response (P = 0.010), longer time to major molecular response (P = 0.012), shorter time to progression (TTP; P = 0.009), and a trend toward lower response rates vs. patients with higher Cmin. A joint effect of prognostic risk score and Cmin on TTP was significant (P < 0.001). Nilotinib Cmin was also associated with the occurrence of all-grade elevations in total bilirubin (P < 0.001) and lipase (P = 0.002) levels. CONCLUSIONS: When tolerability allows, adherence to the nilotinib dose (400 mg twice daily) in order to maintain sufficient Cmin is important in maximizing the efficacy of nilotinib in patients with imatinib-resistant or -intolerant CML.
PURPOSE: We evaluated the population pharmacokinetics (PK) and exposure-response relationship of nilotinib in patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML). METHODS: Concentration data from 493 patients with CML in chronic phase (CML-CP), accelerated phase, or blast crisis were used to perform a population pharmacokinetic analysis using nonlinear mixed-effect modeling. Steady-state nilotinib trough concentrations (Cmin) in individual patients were estimated from the population PK model for correlation with the efficacy and safety variables. Exposure-efficacy analysis was performed in patients with CML-CP, whereas exposure-safety analysis was performed in all patients who had both nilotinib PK data and efficacy/safety measures available. RESULTS: Baseline demographics and CML disease phase did not significantly affect nilotinib PK. Patients with a lower Cmin had significantly longer time to complete cytogenetic response (P = 0.010), longer time to major molecular response (P = 0.012), shorter time to progression (TTP; P = 0.009), and a trend toward lower response rates vs. patients with higher Cmin. A joint effect of prognostic risk score and Cmin on TTP was significant (P < 0.001). Nilotinib Cmin was also associated with the occurrence of all-grade elevations in total bilirubin (P < 0.001) and lipase (P = 0.002) levels. CONCLUSIONS: When tolerability allows, adherence to the nilotinib dose (400 mg twice daily) in order to maintain sufficient Cmin is important in maximizing the efficacy of nilotinib in patients with imatinib-resistant or -intolerant CML.
Authors: Donglu Zhang; Theodore J Chando; Donald W Everett; Christopher J Patten; Shangara S Dehal; W Griffith Humphreys Journal: Drug Metab Dispos Date: 2005-08-23 Impact factor: 3.922
Authors: J Hasford; M Pfirrmann; R Hehlmann; N C Allan; M Baccarani; J C Kluin-Nelemans; G Alimena; J L Steegmann; H Ansari Journal: J Natl Cancer Inst Date: 1998-06-03 Impact factor: 13.506
Authors: C-F Xu; B H Reck; Z Xue; L Huang; K L Baker; M Chen; E P Chen; H E Ellens; V E Mooser; L R Cardon; C F Spraggs; L Pandite Journal: Br J Cancer Date: 2010-04-13 Impact factor: 7.640
Authors: Hagop M Kantarjian; Francis J Giles; Kapil N Bhalla; Javier Pinilla-Ibarz; Richard A Larson; Norbert Gattermann; Oliver G Ottmann; Andreas Hochhaus; Jerald P Radich; Giuseppe Saglio; Timothy P Hughes; Giovanni Martinelli; Dong-Wook Kim; Yaping Shou; Neil J Gallagher; Rick Blakesley; Michele Baccarani; Jorge Cortes; Philipp D le Coutre Journal: Blood Date: 2010-11-22 Impact factor: 22.113
Authors: Paul W Manley; Peter Drueckes; Gabriele Fendrich; Pascal Furet; Janis Liebetanz; Georg Martiny-Baron; Jürgen Mestan; Jörg Trappe; Markus Wartmann; Doriano Fabbro Journal: Biochim Biophys Acta Date: 2009-11-14
Authors: C Tanaka; O Q P Yin; V Sethuraman; T Smith; X Wang; K Grouss; H Kantarjian; F Giles; O G Ottmann; L Galitz; H Schran Journal: Clin Pharmacol Ther Date: 2009-11-18 Impact factor: 6.875
Authors: Huixin Yu; Neeltje Steeghs; Cynthia M Nijenhuis; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema Journal: Clin Pharmacokinet Date: 2014-04 Impact factor: 6.447
Authors: Neeltje Steeghs; Alwin D R Huitema; Stefanie L Groenland; Remy B Verheijen; Markus Joerger; Ron H J Mathijssen; Alex Sparreboom; Jos H Beijnen; Jan H Beumer Journal: Clin Cancer Res Date: 2021-09-21 Impact factor: 12.531
Authors: Christel C L M Boons; Lonneke Timmers; Jeroen J W M Janssen; Eleonora L Swart; Jacqueline G Hugtenburg; N Harry Hendrikse Journal: Eur J Clin Pharmacol Date: 2019-02-07 Impact factor: 2.953
Authors: Christel C L M Boons; Eleonora L Swart; Lonneke Timmers; Peter M van de Ven; Jeroen J W M Janssen; Jacqueline G Hugtenburg Journal: BMC Cancer Date: 2014-04-08 Impact factor: 4.430